<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MDM</journal-id>
<journal-id journal-id-type="hwp">spmdm</journal-id>
<journal-id journal-id-type="nlm-ta">Med Decis Making</journal-id>
<journal-title>Medical Decision Making</journal-title>
<issn pub-type="ppub">0272-989X</issn>
<issn pub-type="epub">1552-681X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0272989X11431609</article-id>
<article-id pub-id-type="publisher-id">10.1177_0272989X11431609</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>How Much Should We Pay for a New HIV Diagnosis? A Mathematical Model of HIV Screening in US Clinical Settings</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Farnham</surname><given-names>Paul G.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Sansom</surname><given-names>Stephanie L.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Hutchinson</surname><given-names>Angela B.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<aff id="aff1-0272989X11431609">Centers for Disease Control and Prevention, Atlanta, Georgia (PGF, SLS, ABH)</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0272989X11431609">Paul G. Farnham, PhD, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, MS E-48, Atlanta, GA 30333; telephone: (404) 639-4201; fax: (404) 639-8642; e-mail: <email>pgf1@cdc.gov</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>32</volume>
<issue>3</issue>
<fpage>459</fpage>
<lpage>469</lpage>
<history>
<date date-type="received">
<day>2</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>10</month>
<year>2011</year>
</date>
</history>
<abstract>
<p><bold>Objective.</bold> To develop a model to assist clinical setting decision makers in determining how much they can spend on human immunodeficiency virus (HIV) screening and still be cost-effective. <bold>Design.</bold> The authors developed a simple mathematical model relating the program cost per new HIV diagnosis to the cost per HIV infection averted and the cost per quality-adjusted life year (QALY) saved by screening. They estimated outcomes based on behavioral changes associated with awareness of HIV infection and applied the model to US sexually transmitted disease clinics. <bold>Methods.</bold> The authors based the cost per new HIV diagnosis (2009 US dollars) on the costs of testing and the proportion of persons who tested positive. Infections averted were calculated from the reduction in annual transmission rates between persons aware and unaware of their infections. The authors defined program costs from the sexually transmitted disease clinic perspective and treatment costs and QALYs saved from the societal perspective. They undertook numerous sensitivity analyses to determine the robustness of the base case results. <bold>Results.</bold> In the base case, the cost per new HIV diagnosis was $2528, the cost per infection averted was $40,516, and the cost per QALY saved was less than zero, or cost-saving. Given the model inputs, the cost per new diagnosis could increase to $22,909 to reach the cost-saving threshold and to $63,053 for the cost-effectiveness threshold. All sensitivity analyses showed that the cost-effectiveness results were consistent for extensive variation in the values of model inputs. <bold>Conclusions.</bold> HIV screening in a clinical setting is cost-effective for a wide range of testing costs, variations in positivity rates, reductions in HIV transmissions, and variation in the receipt of test results.</p>
</abstract>
<kwd-group>
<kwd>HIV</kwd>
<kwd>AIDS</kwd>
<kwd>cost-effectiveness analysis</kwd>
<kwd>cost-utility analysis</kwd>
<kwd>economic aspects of disease</kwd>
<kwd>economics health</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>May–June 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Screening for human immunodeficiency virus (HIV) to detect new infections is a key HIV prevention tool in the United States.<sup><xref ref-type="bibr" rid="bibr1-0272989X11431609">1</xref>,<xref ref-type="bibr" rid="bibr2-0272989X11431609">2</xref></sup> HIV-infected persons who are aware of their status can seek medical care that will improve the length and quality of their lives.<sup><xref ref-type="bibr" rid="bibr3-0272989X11431609">3</xref></sup> Awareness of infection and treatment with antiretroviral therapy can also reduce transmission to uninfected persons.<sup><xref ref-type="bibr" rid="bibr4-0272989X11431609">4</xref><xref ref-type="bibr" rid="bibr5-0272989X11431609"/><xref ref-type="bibr" rid="bibr6-0272989X11431609"/>–<xref ref-type="bibr" rid="bibr7-0272989X11431609">7</xref></sup> Approximately half of new HIV infections are identified through diagnosis in health care settings, such as hospitals, acute care clinics, and sexually transmitted disease (STD) clinics.<sup><xref ref-type="bibr" rid="bibr8-0272989X11431609">8</xref></sup></p>
<p>US public health decision makers and clinic managers, however, are often uncertain about how much they can spend to identify a new case of HIV and still have a cost-effective intervention. Numerous studies have estimated the cost per new HIV diagnosis from screening in different settings. However, these studies vary by the types of tests used, the costs included in the analyses, and the HIV positivity rate.<sup><xref ref-type="bibr" rid="bibr9-0272989X11431609">9</xref><xref ref-type="bibr" rid="bibr10-0272989X11431609"/><xref ref-type="bibr" rid="bibr11-0272989X11431609"/><xref ref-type="bibr" rid="bibr12-0272989X11431609"/>–<xref ref-type="bibr" rid="bibr13-0272989X11431609">13</xref></sup></p>
<p>One of the differences among economic evaluations of HIV testing in clinical settings is whether the sites used conventional HIV antibody tests, which require a return visit for all test results and posttest counseling, or rapid tests that can typically provide negative and preliminary positive results within 30 minutes. In a study of routine HIV screening in Massachusetts urgent care centers, patients were given an oral swab test and required to return within 14 days for test results and posttest counseling,<sup><xref ref-type="bibr" rid="bibr9-0272989X11431609">9</xref></sup> while the 5 sites within a medical center in Mehta and others’ study<sup><xref ref-type="bibr" rid="bibr13-0272989X11431609">13</xref></sup> used conventional and rapid tests. The 2006 Centers for Disease Control and Prevention (CDC) guidelines<sup><xref ref-type="bibr" rid="bibr8-0272989X11431609">8</xref></sup> recommended greater use of rapid tests to increase receipt of HIV test results, given that between 10% and 66% of people tested for HIV with conventional tests never return for their results.<sup><xref ref-type="bibr" rid="bibr14-0272989X11431609">14</xref>,<xref ref-type="bibr" rid="bibr15-0272989X11431609">15</xref></sup> However, Bogart and others<sup><xref ref-type="bibr" rid="bibr16-0272989X11431609">16</xref>,<xref ref-type="bibr" rid="bibr17-0272989X11431609">17</xref></sup> found that from 2003 to 2006, only 52% of hospitals and 17% of community clinics offered rapid tests to their patients.</p>
<p>There is considerable variation in the approaches to measuring the costs of HIV testing among these studies. Farnham and others<sup><xref ref-type="bibr" rid="bibr11-0272989X11431609">11</xref></sup> included only the variable costs of testing, which were drawn from other sources in the literature. Silva and others<sup><xref ref-type="bibr" rid="bibr12-0272989X11431609">12</xref></sup> collected time-motion data to estimate staff labor time for screening and added a 33% administrative cost estimate. Mehta and others<sup><xref ref-type="bibr" rid="bibr13-0272989X11431609">13</xref></sup> did not include materials costs, because HIV counseling, testing supplies, and specimen processing were provided free of charge by the state public health department.</p>
<p>The HIV positivity rate also varies significantly among studies. Farnham and others<sup><xref ref-type="bibr" rid="bibr11-0272989X11431609">11</xref></sup> assumed a rate of 1%, which had been observed in similar settings. The rate was 0.6% in the emergency department studied by Silva and others<sup><xref ref-type="bibr" rid="bibr12-0272989X11431609">12</xref></sup> and varied from 0.6% to 1.5% in the medical center sites of Mehta and others.<sup><xref ref-type="bibr" rid="bibr13-0272989X11431609">13</xref></sup></p>
<p>Public health decision makers often have little knowledge about the values of all of these parameters and how they interact. The cost studies cited above typically did not include analyses of economic evaluation measures, such as the cost per infection averted or the cost per quality-adjusted life year (QALY) saved from screening. To provide guidance, we developed a mathematical model based on the literature<sup><xref ref-type="bibr" rid="bibr18-0272989X11431609">18</xref>,<xref ref-type="bibr" rid="bibr19-0272989X11431609">19</xref></sup> that relates the program cost per new HIV diagnosis to these 2 commonly used economic evaluation measures.<sup><xref ref-type="bibr" rid="bibr20-0272989X11431609">20</xref>,<xref ref-type="bibr" rid="bibr21-0272989X11431609">21</xref></sup> We then applied the model to clinical settings in the United States. Although our base case input values were drawn from data on STD clinics, our input parameters were varied widely to cover the range of inputs in many different clinical settings.</p>
<sec id="section1-0272989X11431609" sec-type="methods">
<title>Methods</title>
<p>We examined the relationships among these variables with a simple mathematical model of HIV screening. Pinkerton and Holtgrave<sup><xref ref-type="bibr" rid="bibr22-0272989X11431609">22</xref></sup> and Pinkerton and others<sup><xref ref-type="bibr" rid="bibr23-0272989X11431609">23</xref></sup> referred to the cost per infection averted as the cost-effectiveness ratio, or <italic>C</italic>/<italic>A</italic>, where <italic>C</italic> is the total program cost of an intervention and <italic>A</italic> is the number of HIV infections averted by the intervention. The cost per QALY gained is the cost-utility ratio, or (<italic>C</italic> − <italic>AT</italic>)/<italic>AQ</italic>, where <italic>C</italic> and <italic>A</italic> are defined as above, while <italic>T</italic> is the HIV treatment cost saved per infection averted and <italic>Q</italic> is the number of QALYs saved per infection averted. These ratios have been estimated for various HIV prevention interventions using relatively simple models<sup><xref ref-type="bibr" rid="bibr24-0272989X11431609">24</xref></sup> and extremely complex models of disease progression and transmission.<sup><xref ref-type="bibr" rid="bibr20-0272989X11431609">20</xref>,<xref ref-type="bibr" rid="bibr21-0272989X11431609">21</xref>,<xref ref-type="bibr" rid="bibr25-0272989X11431609">25</xref>,<xref ref-type="bibr" rid="bibr26-0272989X11431609">26</xref></sup> The cost per infection averted represents a programmatic perspective focusing on the program costs incurred by a testing organization, while the cost per QALY gained represents the societal perspective that includes the overall benefits to society of HIV treatment costs saved and gains in quality of life.</p>
<p>Policy interest focuses on cost per QALY gained values of zero, the threshold between an intervention that is cost saving (a negative cost per QALY gained, where program costs are less than the treatment costs saved by infections averted) and one that requires the use of additional resources to achieve the gain in QALYs (a positive cost per QALY gained). For the latter, $100,000 per QALY saved represents a reasonable current estimate of the amount that society is willing to pay to save a QALY,<sup><xref ref-type="bibr" rid="bibr27-0272989X11431609">27</xref><xref ref-type="bibr" rid="bibr28-0272989X11431609"/>–<xref ref-type="bibr" rid="bibr29-0272989X11431609">29</xref></sup> although this estimate may be conservative.</p>
<p>To examine the cost per HIV infection averted and the cost per QALY gained, we made the following simplifying assumptions in the model: First, rapid tests were used for all screening. This means that all uninfected individuals received their results, and all infected individuals received at least a preliminary positive test result. Second, the model included only the benefits of reduced sexual HIV transmission from index patients who newly learned they were HIV infected. We did not include any direct benefits to index patients from learning their serostatus, such as longer survival or improved quality of life associated with earlier treatment, or any benefits from reduced transmission by injection drug users. Third, the comparator for the economic evaluation was the status quo in the absence of the HIV testing program. Fourth, we assumed that those who were newly diagnosed would otherwise have been diagnosed a year later. Thus, net reductions in transmissions occurred during 1 year only, which was the time frame of the analysis.</p>
<p>We focused on the parameters of the following 2 equations in the analysis. The derivation of the equations and all variable definitions are presented in the <xref ref-type="table" rid="table6-0272989X11431609">appendix</xref>, while the input variable values are shown in <xref ref-type="table" rid="table1-0272989X11431609">Table 1</xref>.</p>
<table-wrap id="table1-0272989X11431609" position="float">
<label>Table 1</label>
<caption>
<p>Input Variables</p>
</caption>
<graphic alternate-form-of="table1-0272989X11431609" xlink:href="10.1177_0272989X11431609-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th align="left">Variable</th>
<th align="center">Base Case Value</th>
<th align="center">Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fraction of population testing positive<sup><xref ref-type="bibr" rid="bibr8-0272989X11431609">8</xref>,<xref ref-type="bibr" rid="bibr33-0272989X11431609">33</xref></sup></td>
<td>0.8</td>
<td>0.1–2.0</td>
</tr>
<tr>
<td colspan="3">Cost of HIV test,<sup><xref ref-type="bibr" rid="bibr11-0272989X11431609">11</xref>,<xref ref-type="bibr" rid="bibr44-0272989X11431609">44</xref>,<xref ref-type="table-fn" rid="table-fn2-0272989X11431609">a</xref></sup></td>
</tr>
<tr>
<td> Positive</td>
<td>85</td>
<td>43–170</td>
</tr>
<tr>
<td> Negative</td>
<td>20</td>
<td>20–80</td>
</tr>
<tr>
<td colspan="3">Fraction of positives</td>
</tr>
<tr>
<td> Testing newly positive<sup><xref ref-type="bibr" rid="bibr37-0272989X11431609">37</xref></sup></td>
<td>100</td>
<td>62.5–100</td>
</tr>
<tr>
<td> Receiving test results<sup><xref ref-type="bibr" rid="bibr41-0272989X11431609">41</xref></sup></td>
<td>100</td>
<td>50–100</td>
</tr>
<tr>
<td>Reduction in annual per person transmission rate<sup><xref ref-type="bibr" rid="bibr18-0272989X11431609">18</xref>,<xref ref-type="bibr" rid="bibr19-0272989X11431609">19</xref>,<xref ref-type="bibr" rid="bibr30-0272989X11431609">30</xref>,<xref ref-type="bibr" rid="bibr31-0272989X11431609">31</xref></sup></td>
<td>6.24</td>
<td>4.68–7.80</td>
</tr>
<tr>
<td>HIV treatment cost per infection averted<sup><xref ref-type="bibr" rid="bibr34-0272989X11431609">34</xref>,<xref ref-type="table-fn" rid="table-fn2-0272989X11431609">a</xref></sup></td>
<td>367,134</td>
<td>Not varied</td>
</tr>
<tr>
<td>No. of quality-adjusted life years saved per infection averted<sup><xref ref-type="bibr" rid="bibr18-0272989X11431609">18</xref>,<xref ref-type="bibr" rid="bibr35-0272989X11431609">35</xref></sup></td>
<td>6.433</td>
<td>Not varied</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0272989X11431609">
<p>Note: Values in percentages unless noted.</p>
</fn>
<fn id="table-fn2-0272989X11431609">
<label>a.</label>
<p>In 2009 dollars.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<list id="list1-0272989X11431609" list-type="order">
<list-item><p>$/HIV infection averted = [(<italic>CPOS</italic>) + [(1 − <italic>p</italic>)/<italic>p</italic>] (<italic>CNEG</italic>)] / (<italic>TRANS</italic>) (<italic>p</italic><sub>N</sub>) (<italic>p</italic><sub>REC</sub>) = ($/new HIV-positive diagnosis) / (<italic>TRANS</italic>) (<italic>p</italic><sub>N</sub>) (<italic>p</italic><sub>REC</sub>)</p></list-item>
<list-item><p>$/QALY = [[(<italic>CPOS</italic>) + [(1 − <italic>p</italic>)/<italic>p</italic>] (<italic>CNEG</italic>)] − [(<italic>TRANS</italic>) (<italic>p</italic><sub>N</sub>) (<italic>p</italic><sub>REC</sub>) (<italic>T</italic>)]] / [(<italic>TRANS</italic>) (<italic>p</italic><sub>N</sub>) (<italic>p</italic><sub>REC</sub>) (<italic>Q</italic>)],</p></list-item>
</list>
<p>where</p>
<p>$/HIV infection averted = cost per HIV infection averted</p>
<p>$/QALY = cost per QALY saved from HIV infections averted</p>
<p><italic>CPOS</italic> = cost of a positive HIV test</p>
<p><italic>CNEG</italic> = cost of a negative HIV test</p>
<p><italic>p</italic> = fraction of population testing positive</p>
<p><italic>p</italic><sub>N</sub> = fraction of positives testing newly positive</p>
<p><italic>p</italic><sub>REC</sub> = fraction of positives receiving test results</p>
<p><italic>TRANS</italic> = reduction in annual per person transmission rate from testing and awareness of infection</p>
<p>$/new HIV-positive diagnosis = <italic>CPOS</italic> + [(1 − <italic>p</italic>)/<italic>p</italic>] <italic>CNEG</italic></p>
<p><italic>T</italic> = HIV treatment cost per infection averted</p>
<p><italic>Q</italic> = number of QALYs saved per HIV infection averted.</p>
<p>Equation 1 represents Pinkerton and others’ cost per infection averted,<sup><xref ref-type="bibr" rid="bibr23-0272989X11431609">23</xref></sup> <italic>C</italic>/<italic>A</italic>, while equation 2 is their cost-utility ratio, (<italic>C</italic> − <italic>AT</italic>)/<italic>AQ</italic>. We measured all costs in 2009 US dollars.</p>
<p>The approach for estimating infections averted from the reduction in transmission rates was based on differences in transmission rates by knowledge of HIV serostatus. Pinkerton<sup><xref ref-type="bibr" rid="bibr30-0272989X11431609">30</xref></sup> developed a model, updated by Prabhu and others,<sup><xref ref-type="bibr" rid="bibr31-0272989X11431609">31</xref></sup> deriving an annual per-person sexual transmission rate of 8.77% for those unaware of their serostatus and 2.53% for those aware. Annual transmission rates, defined as the average number of HIV transmissions or new infections per person living with HIV, were based on HIV incidence and prevalence surveillance data and the proportion of people who were unaware of their HIV infection. Rates were defined for the following categories: those acutely infected and unaware of their infection, those nonacutely infected and unaware of their infection, and those nonacutely infected and aware. Because the acute phase lasts an average of 49 days,<sup><xref ref-type="bibr" rid="bibr30-0272989X11431609">30</xref></sup> our analysis focused on the transmission differences between nonacute unaware and aware persons.</p>
<p>The transmission rate ratio for nonacute unaware to nonacute aware persons was based on estimates by Marks and others<sup><xref ref-type="bibr" rid="bibr4-0272989X11431609">4</xref></sup> such that transmission rates for persons unaware of their infection were more than 3 times greater than rates for persons aware of their infection. In their analysis, Marks and others <sup><xref ref-type="bibr" rid="bibr4-0272989X11431609">4</xref></sup>estimated the proportion of HIV-infected aware persons in the United States who could transmit to at-risk partners that was derived from the proportion who were in medical care (60%) and the proportion of those whose viral load was low enough to prevent transmission (54.5%). Marks and others<sup><xref ref-type="bibr" rid="bibr4-0272989X11431609">4</xref></sup> included the assumption, based on a previous meta-analysis,<sup><xref ref-type="bibr" rid="bibr32-0272989X11431609">32</xref></sup> that there was a 57% reduction in the prevalence of unprotected intercourse with at-risk partners among HIV-infected aware persons relative to the prevalence among HIV-infected unaware persons.</p>
<p>The difference between the unaware and aware sexual transmission rates (6.24%) was used to estimate HIV infections averted in this model. This approach was based on the work of Hutchinson and others,<sup><xref ref-type="bibr" rid="bibr18-0272989X11431609">18</xref></sup> who used this method to estimate the transmission benefits from testing for acute HIV infection. Holtgrave,<sup><xref ref-type="bibr" rid="bibr19-0272989X11431609">19</xref></sup> who used a comparable approach to estimate the impact of the CDC’s recommendations for opt-out testing in health care settings, used a transmission rate reduction of 6.4%. Although all infected persons in our model were assumed to incur the costs of testing, reduced transmission from knowledge of serostatus applied only to those who were newly aware of their serostatus and who received their test results.</p>
<p>We used STD clinic setting data for the other variables in the base case analysis (<xref ref-type="table" rid="table1-0272989X11431609">Table 1</xref>). Costs of a rapid HIV test, positive ($85) and negative ($20), were derived from Farnham and others<sup><xref ref-type="bibr" rid="bibr11-0272989X11431609">11</xref></sup> updated to 2009 dollars. These costs included only the marginal costs of using rapid HIV tests in the STD clinic setting—that is, the costs for collecting specimens, the test kits, and the confirmatory tests and posttest counseling for infected persons. We did not include the cost of administrative overhead. Rapid test kit costs were based on the General Service Administration schedule for the Unigold and OraQuick tests. Costs for a positive test were higher than those for a negative test due to the costs of confirmatory testing and additional posttest counseling for infected persons.<sup><xref ref-type="bibr" rid="bibr11-0272989X11431609">11</xref></sup></p>
<p>We based the fraction of the population testing positive (0.8%) on data from STD clinics in Seattle.<sup><xref ref-type="bibr" rid="bibr33-0272989X11431609">33</xref></sup> In the base case, we assumed that all HIV-infected persons were newly diagnosed and received their test results. We used discounted lifetime treatment costs saved per HIV infection averted ($367,134) from Schackman and others,<sup><xref ref-type="bibr" rid="bibr34-0272989X11431609">34</xref></sup> updated to 2009 dollars. These costs were based on an estimated life expectancy of 32.1 years from the time of infection and were discounted at 3%. The number of QALYs saved per HIV infection averted (6.433), also discounted at 3%, was based on Hutchinson and others,<sup><xref ref-type="bibr" rid="bibr18-0272989X11431609">18</xref></sup> who used utility weights by Tengs and Lin,<sup><xref ref-type="bibr" rid="bibr35-0272989X11431609">35</xref></sup> and assumed that 35 years was the average age at which a person would become infected and that additional life expectancy was 32 years for persons infected with HIV and 44.6 years for those who were uninfected.</p>
<p>In the base case analysis, we used the above parameters to calculate the cost per new HIV diagnosis, the cost per infection averted, and the cost per QALY gained. We did a 1-way threshold sensitivity analysis for the following parameters in equations 1 and 2 to find those values that resulted in cost per QALY values of either zero or $100,000: the fraction of the population testing positive, the costs of positive and negative HIV tests, the fraction of those infected testing newly positive, the fraction of those infected receiving their test results, and the reduction in the annual per-person transmission rate. The reduction in transmission applies only to those infected persons who newly learn their HIV status and who receive their test results. Substantial repeat testing by HIV-infected persons has been observed in different settings,<sup><xref ref-type="bibr" rid="bibr36-0272989X11431609">36</xref>,<xref ref-type="bibr" rid="bibr37-0272989X11431609">37</xref></sup> which could be related to the need for persons to confirm their infection before initiating treatment or to qualify for social service benefits or as a response to financial incentives offered to encourage HIV testing.<sup><xref ref-type="bibr" rid="bibr38-0272989X11431609">38</xref></sup></p>
<p>We did not do a sensitivity analysis on HIV treatment costs or QALYs saved per infection averted, because these variables are not really independent parameters, as noted by Holtgrave and Pinkerton,<sup><xref ref-type="bibr" rid="bibr39-0272989X11431609">39</xref></sup> and should not be varied separately. We did not vary the discount rate for either of these variables, because 3% is standard for health care analyses<sup><xref ref-type="bibr" rid="bibr40-0272989X11431609">40</xref></sup> and because these variables were drawn from other complex models where the exact time pattern of values was unknown.<sup><xref ref-type="bibr" rid="bibr34-0272989X11431609">34</xref></sup></p>
<p>We did 2-way sensitivity analyses on selected variables based on their least favorable cost-effective values in <xref ref-type="table" rid="table1-0272989X11431609">Table 1</xref>. For the multiway sensitivity analyses, we did best- and worst-case scenarios using the most and least favorable cost-effectiveness values of the <xref ref-type="table" rid="table1-0272989X11431609">Table 1</xref> variables. We also did probabilistic sensitivity analyses of 1000 iterations, drawing equally distributed random values from the range of values for the <xref ref-type="table" rid="table1-0272989X11431609">Table 1</xref> variables. We used a uniform distribution because we wanted to examine the full potential effect of variation in the testing parameters in different settings and regions in the United States. Given the limited data on these parameters, the lack of reported results about how they would vary across testing sites, and the fact that some of our base case values were lower- or upper-bound values, we chose a uniform distribution to give equal weight to the values within the selected range. Because of the variation in the use of rapid and conventional tests in the United States noted above, we developed a conventional test base case scenario using conventional test cost parameters<sup><xref ref-type="bibr" rid="bibr11-0272989X11431609">11</xref></sup> and return rates<sup><xref ref-type="bibr" rid="bibr41-0272989X11431609">41</xref></sup> to examine any possible differences with the rapid test scenario. We also did a probabilistic sensitivity analysis for the conventional test scenario. All analyses were conducted with Microsoft Excel 2007.</p>
</sec>
<sec id="section2-0272989X11431609" sec-type="results">
<title>Results</title>
<p>Using the base case values for all parameters, the cost per new HIV-positive diagnosis was $2528; the cost per infection averted was $40,516; and the cost per QALY saved was –$50,772, or cost saving (<xref ref-type="table" rid="table2-0272989X11431609">Table 2</xref>). The expression [(1 − <italic>p</italic>)/<italic>p</italic>] in equations 1 and 2, where <italic>p</italic> is the fraction of the population testing positive, shows the number of uninfected persons who would have to be tested to identify 1 infected person (124 in the base case).</p>
<table-wrap id="table2-0272989X11431609" position="float">
<label>Table 2</label>
<caption>
<p>Model Results: Base Case</p>
</caption>
<graphic alternate-form-of="table2-0272989X11431609" xlink:href="10.1177_0272989X11431609-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Outcome Variable</th>
<th align="center">Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>New HIV-positive diagnosis</td>
<td>2528</td>
</tr>
<tr>
<td>HIV infection averted</td>
<td>40,516</td>
</tr>
<tr>
<td>Quality-adjusted life year saved</td>
<td>−50,772</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0272989X11431609">
<p>Note: In 2009 dollars.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In the 1-way threshold sensitivity analysis (<xref ref-type="table" rid="table3-0272989X11431609">Table 3</xref>), the fraction of the population testing positive (assuming all were newly diagnosed) could be lowered from its base case value of 0.8% down to 0.09% to reach a cost per QALY value of zero (the threshold for cost savings). This change resulted in a cost per positive diagnosis of $22,909 and a cost per infection averted value of $367,134. Almost 1200 uninfected people would have to be tested to identify each infected person in this case. To reach a cost per QALY value of $100,000 (the potential threshold for cost-effectiveness), it was necessary to lower the fraction of the population testing positive (assuming all were newly diagnosed) to 0.03%. The resulting cost per positive diagnosis was $63,053, and the cost per infection averted was $1,010,458. Approximately 3200 uninfected persons would have to be tested to identify each infected individual in this case.</p>
<table-wrap id="table3-0272989X11431609" position="float">
<label>Table 3</label>
<caption>
<p>One-Way Sensitivity Analysis Thresholds</p>
</caption>
<graphic alternate-form-of="table3-0272989X11431609" xlink:href="10.1177_0272989X11431609-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="2">Threshold Where $ / Quality-Adjusted Life Year Saved =</th>
</tr>
<tr>
<th align="left">Input Variable</th>
<th align="center">Base Case</th>
<th align="center">$0</th>
<th align="center">$100,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fraction of population testing positive</td>
<td>0.8</td>
<td>0.09</td>
<td>0.03</td>
</tr>
<tr>
<td colspan="4">Cost of a HIV test<sup><xref ref-type="table-fn" rid="table-fn5-0272989X11431609">a</xref></sup></td>
</tr>
<tr>
<td> Positive</td>
<td>85</td>
<td>20,466</td>
<td>60,610</td>
</tr>
<tr>
<td> Negative</td>
<td>20</td>
<td>184</td>
<td>508</td>
</tr>
<tr>
<td colspan="4">Fraction of positives</td>
</tr>
<tr>
<td> Testing newly positive</td>
<td>100</td>
<td>11</td>
<td>4</td>
</tr>
<tr>
<td> Receiving test results</td>
<td>100</td>
<td>11</td>
<td>4</td>
</tr>
<tr>
<td>Reduction in annual per-person transmission rate</td>
<td>6.24</td>
<td>0.69</td>
<td>0.25</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0272989X11431609">
<p>Note: Values in percentages unless noted.</p>
</fn>
<fn id="table-fn5-0272989X11431609">
<label>a.</label>
<p>In 2009 dollars.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>All else constant, the cost of a negative test had to be increased to $184 for the cost per QALY gained to equal zero and to $508 for the cost per QALY to equal $100,000. The corresponding required values for the cost of a positive test were $20,466 and $60,610; for the reduction in the annual per-person transmission rate, 0.69% and 0.25%; and for the fraction of infected people testing newly positive and the fraction of positives receiving test results, 11% and 4%.</p>
<p><xref ref-type="table" rid="table4-0272989X11431609">Table 4</xref> presents the results of the 2-way sensitivity analyses where we varied combinations of input variables based on their least favorable cost-effective values in <xref ref-type="table" rid="table1-0272989X11431609">Table 1</xref>. When the fraction of the population testing positive was varied with the reduction in the annual per-person transmission rate, test costs, and the fraction of positives receiving test results (<xref ref-type="table" rid="table4-0272989X11431609">Table 4</xref>), there was a positive cost per QALY saved. However, only the lowest value of the fraction of the population testing positive and the highest test cost values resulted in a cost per QALY saved that exceeded the cost-effectiveness threshold. When we used the lowest values of the fraction of positives receiving test results, the reduction in the annual per-person transmission rate, and the fraction of positives testing newly positive, screening continued to be cost-saving, even with the reduced values of these variables.</p>
<table-wrap id="table4-0272989X11431609" position="float">
<label>Table 4</label>
<caption>
<p>Two-Way Sensitivity Analysis</p>
</caption>
<graphic alternate-form-of="table4-0272989X11431609" xlink:href="10.1177_0272989X11431609-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="3">Costs per . . .</th>
</tr>
<tr>
<th align="left">Value of Input Variable 1</th>
<th align="left">Value of Input Variable 2</th>
<th align="center">New HIV Diagnosis<sup><xref ref-type="table-fn" rid="table-fn7-0272989X11431609">a</xref></sup></th>
<th align="center">Infection Averted<sup><xref ref-type="table-fn" rid="table-fn8-0272989X11431609">b</xref></sup></th>
<th align="center">Quality-Adjusted Life Year Saved<sup><xref ref-type="table-fn" rid="table-fn9-0272989X11431609">c</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fraction of population testing positive (0.1%)</td>
<td>Reduction in annual per person transmission rate (4.68%)</td>
<td>19,766</td>
<td>422,344</td>
<td>8582</td>
</tr>
<tr>
<td/>
<td>Cost of a positive HIV test ($170), negative HIV test ($80)</td>
<td>80,090</td>
<td>1,283,494</td>
<td>142,447</td>
</tr>
<tr>
<td/>
<td>Fraction of positives receiving test results (50%)</td>
<td>19,766</td>
<td>633,516</td>
<td>41,409</td>
</tr>
<tr>
<td>Fraction of positives receiving test results (50%)</td>
<td>Reduction in annual per person transmission rate (4.68%)</td>
<td>2528</td>
<td>108,043</td>
<td>−40,275</td>
</tr>
<tr>
<td/>
<td>Fraction of positives testing newly positive (62.5%)</td>
<td>2528</td>
<td>129,651</td>
<td>−36,916</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0272989X11431609">
<p>Note: Costs in 2009 dollars.</p>
</fn>
<fn id="table-fn7-0272989X11431609">
<label>a.</label>
<p>Base case value: $2528.</p>
</fn>
<fn id="table-fn8-0272989X11431609">
<label>b.</label>
<p>Base case value: $40,516.</p>
</fn>
<fn id="table-fn9-0272989X11431609">
<label>c.</label>
<p>Base case value: –$50,772.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="table" rid="table5-0272989X11431609">Table 5</xref> presents the best- and worst-case scenarios and the probabilistic sensitivity analysis for the rapid test scenario and the 2 analyses for the conventional test scenario. The best-case values for the rapid test scenario showed a negative cost per QALY saved, while the worst-case values showed a positive cost per QALY that far exceeded the cost-effectiveness threshold. The average cost per QALY from the rapid test probabilistic sensitivity analysis confirmed the base case results. In simulations of 1000 iterations, the average cost per new HIV-positive diagnosis was approximately $8000, and the cost per QALY saved was always negative.</p>
<table-wrap id="table5-0272989X11431609" position="float">
<label>Table 5</label>
<caption>
<p>Multiway Sensitivity Analysis</p>
</caption>
<graphic alternate-form-of="table5-0272989X11431609" xlink:href="10.1177_0272989X11431609-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3">Rapid Test Scenario</th>
<th align="center" colspan="2">Conventional Test Scenario</th>
</tr>
<tr>
<th align="left">Input Variable Values</th>
<th align="center">Best Case</th>
<th align="center">Worst Case</th>
<th align="center">Average Value Probabilistic SA</th>
<th align="center">Base Case</th>
<th align="center">Average Value Probabilistic SA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fraction of population testing positive</td>
<td>2</td>
<td>0.1</td>
<td>1</td>
<td>0.8</td>
<td>1</td>
</tr>
<tr>
<td colspan="6">Cost of a HIV test<sup><xref ref-type="table-fn" rid="table-fn11-0272989X11431609">a</xref></sup></td>
</tr>
<tr>
<td> Positive</td>
<td>43</td>
<td>170</td>
<td>107</td>
<td>74</td>
<td>93</td>
</tr>
<tr>
<td> Negative</td>
<td>20</td>
<td>80</td>
<td>49</td>
<td>15</td>
<td>38</td>
</tr>
<tr>
<td colspan="6">Fraction of positives</td>
</tr>
<tr>
<td> Testing newly positive</td>
<td>100</td>
<td>62.5</td>
<td>81.2</td>
<td>100</td>
<td>81.9</td>
</tr>
<tr>
<td> Receiving test results</td>
<td>100</td>
<td>50</td>
<td>76.3</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Reduction in annual per person transmission rate</td>
<td>7.80</td>
<td>4.68</td>
<td>6.21</td>
<td>6.24</td>
<td>6.26</td>
</tr>
<tr>
<td colspan="6">Output variable values: Costs per . . . <sup><xref ref-type="table-fn" rid="table-fn11-0272989X11431609">a</xref></sup></td>
</tr>
<tr>
<td> New HIV-positive diagnosis</td>
<td>1008</td>
<td>80,090</td>
<td>8074</td>
<td>1876</td>
<td>5911</td>
</tr>
<tr>
<td> HIV infection averted</td>
<td>12,921</td>
<td>5,476,239</td>
<td>225,768</td>
<td>60,121</td>
<td>249,202</td>
</tr>
<tr>
<td> Quality-adjusted life year saved</td>
<td>−55,062</td>
<td>794,203</td>
<td>−21,975</td>
<td>−47,725</td>
<td>−18,332</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn10-0272989X11431609">
<p>Note: Values in percentages unless noted. SA, sensitivity analysis.</p>
</fn>
<fn id="table-fn11-0272989X11431609">
<label>a.</label>
<p>In 2009 dollars.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The conventional test scenario results were based on conventional test costs that were somewhat lower than those for the rapid test<sup><xref ref-type="bibr" rid="bibr11-0272989X11431609">11</xref></sup> and a return rate that was an average drawn from the results of 4 studies in the literature.<sup><xref ref-type="bibr" rid="bibr41-0272989X11431609">41</xref></sup> The base case conventional test results (<xref ref-type="table" rid="table5-0272989X11431609">Table 5</xref>) were similar to those for the rapid test scenario (<xref ref-type="table" rid="table2-0272989X11431609">Table 2</xref>). Although the conventional test analysis used a receipt of results rate of 50% compared to 100% with the rapid test, the lower conventional test costs resulted in a cost per new HIV-positive diagnosis of approximately $1900 and a negative cost per QALY saved approximately the same size as in the rapid test scenario. The average probabilistic sensitivity analysis values for the conventional test were also similar to those for the rapid test (<xref ref-type="table" rid="table5-0272989X11431609">Table 5</xref>), both indicating that screening was cost-saving.</p>
</sec>
<sec id="section3-0272989X11431609" sec-type="discussion">
<title>Discussion</title>
<p>This research has shown that HIV screening in a clinical setting is cost-saving or cost-effective for a wide range of testing costs, variations in positivity rates, reductions in HIV transmission, and variation in the receipt of test results. These ranges include test costs that are substantially higher than current values and HIV positivity rates down to the minimum value for screening (0.1%) recommended by the CDC.<sup><xref ref-type="bibr" rid="bibr8-0272989X11431609">8</xref></sup> These results hold for greatly reduced values of HIV infections averted and lower-than-expected rates of receipt of conventional and rapid test results.</p>
<p>For an HIV screening intervention to have a cost per QALY gained equal to zero (the threshold for cost savings), the program cost per infection averted has to equal the HIV treatment cost per infection averted. If infections averted were held constant, this equality could have been achieved in our model if the cost per new positive diagnosis increased to $22,909, or 9 times the base case value. This increase could have occurred 1) if screening were undertaken in populations with positivity rates down to only one-tenth the size of the base case value and less than the minimum screening positivity rate of 0.1% in the 2006 CDC recommendations,<sup><xref ref-type="bibr" rid="bibr8-0272989X11431609">8</xref></sup> 2) for values of the cost of a negative test that were 9 times the size of the base case value, and 3) for values of the cost of a positive test that were 240 times the size of the base case value.</p>
<p>The impact of changes in the cost of a positive test on the cost per QALY gained was much less than for changes in the cost of a negative test, particularly at low positivity rates. At the base case positivity rate of 0.8%, 124 uninfected persons must be tested to identify 1 infected person, whereas at a prevalence of 0.08%, the number of uninfected persons tested increases to 1249. Thus, any change in the cost of a negative test would affect a far larger number of persons than a change in the cost of a positive test.</p>
<p>The number of infections averted from awareness of serostatus could also vary substantially in our model while leaving the screening intervention cost-saving. Thus, even if the reduction in transmission from knowledge of serostatus is not as great as that estimated by Marks and others,<sup><xref ref-type="bibr" rid="bibr4-0272989X11431609">4</xref></sup> the impact on cost per QALY saved is minimal. Although we assumed in the base case that the reduction in transmission applied to the 100% of infected persons who newly learned their serostatus and received their test results, the value of each of these variables could decrease to 11%, all else constant, before the cost per QALY saved equaled zero.</p>
<p>The 2-way and multiway sensitivity analyses strengthened the 1-way threshold results. In the 2-way analyses, screening was found to exceed the cost-effectiveness threshold only when we used the minimum value for the fraction of the population testing positive in the 2006 CDC screening recommendations (0.1%) and for positive test costs that were double and negative test costs that were 4 times the size of the base case values.</p>
<p>Although the worst-case scenario results for the rapid test were also not cost-effective, it is highly unlikely that all of the input variables would take their worst-case values simultaneously. In this scenario, the fraction of the population testing positive was again at the minimum CDC screening recommendation of 0.1%. Patel and others<sup><xref ref-type="bibr" rid="bibr42-0272989X11431609">42</xref></sup> found positivity rates of 3.0% at the San Francisco City Clinic and 0.87% at 3 Los Angeles STD clinics and the MSM (men who have sex with men) unit of the Los Angeles County Men’s Central Jail in 2003–2004. During this same period, Campos-Outcalt and others<sup><xref ref-type="bibr" rid="bibr43-0272989X11431609">43</xref></sup> found a rate of 0.56% at the Maricopa County STD clinic in Arizona. Hutchinson and others<sup><xref ref-type="bibr" rid="bibr18-0272989X11431609">18</xref></sup> estimated a positivity rate of 1.2% at their HIV counseling and testing sites, 1.0% at municipal STD clinics, and 1.8% at a community clinic serving MSM in Los Angeles. In the 25 jurisdictions funded by CDC’s Expanded Testing Initiative, the new positive test rate averaged 0.6% in clinical settings.<sup><xref ref-type="bibr" rid="bibr37-0272989X11431609">37</xref></sup></p>
<p>Regarding the other variables in the worst-case scenario, Pinkerton and others<sup><xref ref-type="bibr" rid="bibr44-0272989X11431609">44</xref></sup> estimated that the mean cost of a rapid test and counseling at 45 study hospitals was $48.07 for a negative test and $64.17 for a preliminary positive test (2006 US dollars). Negative test costs ranged from $27.64 to $87.94, while preliminary positive test costs varied from $29.07 to $113.74. These estimates are generally below the values used in the worst-case scenario. The fraction of positives receiving their rapid test results in the worst-case scenario (50%) was the average rate for conventional tests in the meta-analysis of Hutchinson and others.<sup><xref ref-type="bibr" rid="bibr41-0272989X11431609">41</xref></sup> However, use of rapid tests implies a receipt of results rate of essentially 100%.</p>
<p>This analysis is limited because it focused only on the immediate, 1-year impact of an HIV testing program. We assumed that those who were newly diagnosed would otherwise have been diagnosed a year later. This is a conservative assumption that applies primarily to groups such as high-risk MSM.<sup><xref ref-type="bibr" rid="bibr45-0272989X11431609">45</xref></sup> To extend the analysis, we would need to consider additional assumptions about when persons would otherwise have been tested, as Hutchinson and others<sup><xref ref-type="bibr" rid="bibr18-0272989X11431609">18</xref></sup> did in their analysis of screening for acute infection.</p>
<p>Assuming that diagnosis would not have otherwise occurred until further in the future would require closer examination of the benefits of linkage to care and treatment of the index persons, as well as an analysis of additional transmission dynamics. Impacts of testing on index persons can be analyzed with the more complex disease progression models in the published literature.<sup><xref ref-type="bibr" rid="bibr20-0272989X11431609">20</xref>,<xref ref-type="bibr" rid="bibr21-0272989X11431609">21</xref>,<xref ref-type="bibr" rid="bibr26-0272989X11431609">26</xref></sup> These models can examine changes in the types of treatment costs over a person’s lifetime (inpatient utilization, antiretroviral therapy, etc.), all of which we have summarized in this simple model with a lifetime treatment cost estimate.<sup><xref ref-type="bibr" rid="bibr34-0272989X11431609">34</xref></sup> Over a longer period, additional secondary transmissions might also be prevented from index persons who were now aware of their status. However, some of the infections averted in our model may only be delayed. Use of dynamic transmission models<sup><xref ref-type="bibr" rid="bibr46-0272989X11431609">46</xref></sup> could improve estimates of the cost-effectiveness of screening but would introduce additional complexity and uncertainty related to other factors, such as sexual mixing patterns, which are often not well defined.</p>
<p>Other costs of testing, including fixed costs and those for recruitment and outreach, could be added to the model. However, the range of variable costs included in our sensitivity analysis was substantial and applies to many clinical settings.<sup><xref ref-type="bibr" rid="bibr47-0272989X11431609">47</xref></sup></p>
<p>The transmissions averted variable could also be adjusted to reflect differences in transmission rates among specific risk groups, such as MSM. Use of the current rate is somewhat conservative in that it reflects both heterosexual and MSM transmission. The current analysis also did not include injection drug user transmission, which represents approximately 13% of all transmissions.<sup><xref ref-type="bibr" rid="bibr48-0272989X11431609">48</xref></sup></p>
<p>In conclusion, given the input values in this study, the cost per new HIV diagnosis can increase up to $22,909 in clinical settings and still be cost-saving and up to $63,053 and still be cost-effective. Because HIV is expensive to treat and because diagnosis appears to reduce transmission to partners, the program costs per infection averted are typically small relative to the treatment costs per infection averted. HIV screening in clinical settings appears to be an efficient use of prevention resources over a wide range of costs and in settings with substantially varying HIV positivity rates.</p>
</sec>
</body>
<back>
<app-group>
<table-wrap id="table6-0272989X11431609" position="float">
<label>Appendix</label>
<caption>
<p>Calculation of Cost per HIV Infection Averted and Cost per Quality-Adjusted Life Year Saved</p>
</caption>
<graphic alternate-form-of="table6-0272989X11431609" xlink:href="10.1177_0272989X11431609-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Variable Definitions</td>
<td/>
</tr>
<tr>
<td>$/HIV infection averted</td>
<td>Cost per HIV infection averted</td>
</tr>
<tr>
<td>$/QALY saved</td>
<td>
Cost per quality-adjusted life year (QALY) saved from HIV infections averted</td>
</tr>
<tr>
<td><italic>TNPOS</italic></td>
<td>Number of persons newly testing positive</td>
</tr>
<tr>
<td><italic>TRPOS</italic></td>
<td>Number of persons repeat testing positive</td>
</tr>
<tr>
<td><italic>TPOS</italic></td>
<td>Number of persons testing positive = <italic>TNPOS</italic> + <italic>TRPOS</italic></td>
</tr>
<tr>
<td><italic>TPOP</italic></td>
<td>Number of persons in the total population</td>
</tr>
<tr>
<td><italic>TNEG</italic></td>
<td>Number of persons testing negative = <italic>TPOP</italic> − <italic>TPOS</italic></td>
</tr>
<tr>
<td><italic>TREC</italic></td>
<td>Number of persons testing positive who receive test results</td>
</tr>
<tr>
<td><italic>p</italic></td>
<td>Fraction of population testing positive = <italic>TPOS</italic>/<italic>TPOP</italic></td>
</tr>
<tr>
<td>1 − <italic>p</italic></td>
<td>Fraction of population testing negative = 1 − <italic>TPOS</italic> / <italic>TPOP</italic></td>
</tr>
<tr>
<td><italic>p</italic><sub>N</sub></td>
<td>Fraction of positives testing newly positive = <italic>TNPOS</italic> / <italic>TPOS</italic></td>
</tr>
<tr>
<td><italic>p</italic><sub>R</sub></td>
<td>Fraction of positives testing repeat positive = <italic>TRPOS</italic> / <italic>TPOS</italic></td>
</tr>
<tr>
<td>1 = <italic>p</italic><sub>N</sub> + <italic>p</italic><sub>R</sub></td>
<td><italic>TNPOS</italic> / <italic>TPOS</italic> + <italic>TRPOS</italic> / <italic>TPOS</italic> = (<italic>TNPOS</italic> + <italic>TRPOS</italic>) / <italic>TPOS</italic> = <italic>TPOS</italic>/<italic>TPOS</italic> = 1</td>
</tr>
<tr>
<td><italic>p</italic><sub>NPOP</sub></td>
<td>Fraction of population testing newly positive = <italic>TNPOS</italic> / <italic>TPOP</italic> = (<italic>p</italic>) (<italic>p</italic><sub>N</sub>) = (<italic>TPOS</italic> / <italic>TPOP</italic>) (<italic>TNPOS</italic> / <italic>TPOS</italic>)</td>
</tr>
<tr>
<td><italic>p</italic><sub>RPOP</sub></td>
<td>Fraction of population testing repeat positive = <italic>TRPOS</italic> / <italic>TPOP</italic> = (<italic>p</italic>) (<italic>p</italic><sub>R</sub>) = (<italic>TPOS</italic> / <italic>TPOP</italic>) (<italic>TRPOS</italic> / <italic>TPOS</italic>)</td>
</tr>
<tr>
<td><italic>p</italic> = <italic>p</italic><sub>NPOP</sub> + <italic>p</italic><sub>RPOP</sub></td>
<td>(<italic>TNPOS</italic> / <italic>TPOP</italic>) + (<italic>TRPOS</italic> / <italic>TPOP</italic>) = (<italic>TNPOS</italic> + <italic>TRPOS</italic>) / <italic>TPOP</italic> = <italic>TPOS</italic> / <italic>TPOP</italic></td>
</tr>
<tr>
<td><italic>p</italic><sub>REC</sub></td>
<td>Fraction of positives receiving test results = <italic>TREC</italic> / <italic>TPOS</italic></td>
</tr>
<tr>
<td><italic>CPOS</italic></td>
<td>Cost of a positive test</td>
</tr>
<tr>
<td><italic>CNEG</italic></td>
<td>Cost of a negative test</td>
</tr>
<tr>
<td><italic>Tu</italic></td>
<td>Annual per person transmission rate for those unaware of their serostatus</td>
</tr>
<tr>
<td><italic>Ta</italic></td>
<td>Annual per person transmission rate for those newly aware of their serostatus</td>
</tr>
<tr>
<td><italic>TRANS</italic></td>
<td>Reduction in annual per person transmission rate from testing and new awareness of infection = <italic>Tu – Ta</italic></td>
</tr>
<tr>
<td><italic>Q</italic></td>
<td>Number of QALYS saved per HIV infection averted</td>
</tr>
<tr>
<td><italic>C</italic></td>
<td>Total program cost of testing a given population</td>
</tr>
<tr>
<td><italic>T</italic></td>
<td>HIV treatment cost per infection averted</td>
</tr>
<tr>
<td>$/HIV-positive diagnosis</td>
<td>Cost per new HIV-positive diagnosis</td>
</tr>
<tr>
<th align="left" colspan="2">Calculation of Cost per HIV Infection Averted</th>
</tr>
<tr>
<td colspan="2">C = (<italic>TPOS</italic>) (<italic>CPOS</italic>) + (<italic>TNEG</italic>) (<italic>CNEG</italic>)</td>
</tr>
<tr>
<td colspan="2">C = (<italic>TPOS</italic>) (<italic>CPOS</italic>) + (<italic>TPOP</italic> − <italic>TPOS</italic>) (<italic>CNEG</italic>)</td>
</tr>
<tr>
<td colspan="2">$/HIV infection averted = <italic>C</italic> / [(<italic>TRANS</italic>) (<italic>TNPOS</italic>) (<italic>TREC</italic> / <italic>TPOS</italic>)]</td>
</tr>
<tr>
<td colspan="2">$/HIV infection averted = [(<italic>TPOS</italic>) (<italic>CPOS</italic>) + (<italic>TPOP</italic> − <italic>TPOS</italic>) (<italic>CNEG</italic>)] / [(<italic>TRANS</italic>) (<italic>TNPOS</italic>) (<italic>p</italic><sub>REC</sub>)]</td>
</tr>
<tr>
<td colspan="2">Divide numerator and denominator by <italic>TPOP</italic></td>
</tr>
<tr>
<td colspan="2">$/HIV infection averted = [(<italic>p</italic>) (<italic>CPOS</italic>) + (1 − <italic>p</italic>) (<italic>CNEG</italic>)] / [(<italic>TRANS</italic>) (<italic>p</italic><sub>NPOP</sub>) (<italic>p</italic><sub>REC</sub>)]</td>
</tr>
<tr>
<td colspan="2">$/HIV infection averted = [(<italic>p</italic>) (<italic>CPOS</italic>) + (1 − <italic>p</italic>) (<italic>CNEG</italic>)] / [(<italic>TRANS</italic>) (<italic>p</italic>) (<italic>p</italic><sub>N</sub>) (<italic>p</italic><sub>REC</sub>)]</td>
</tr>
<tr>
<td colspan="2">Divide numerator and denominator by (<italic>p</italic>)</td>
</tr>
<tr>
<td colspan="2">$/HIV infection averted = [(<italic>CPOS</italic>) + [(1 − <italic>p</italic>) / <italic>p</italic>] (<italic>CNEG</italic>)] / (<italic>TRANS</italic>) (<italic>p</italic><sub>N</sub>) (<italic>p</italic><sub>REC</sub>) = $/new HIV-positive diagnosis / (<italic>TRANS</italic>) (<italic>p</italic><sub>N</sub>) (<italic>p</italic><sub>REC</sub>) where $/new HIV-positive diagnosis = (<italic>CPOS</italic>) + [(1 − <italic>p</italic>) / <italic>p</italic>] (<italic>CNEG</italic>)</td>
</tr>
<tr>
<th align="left" colspan="2">Calculation of Cost per QALY Saved</th>
</tr>
<tr>
<td colspan="2">$/QALY saved = [[(<italic>TPOS</italic>) (<italic>CPOS</italic>) + (<italic>TPOP</italic> − <italic>TPOS</italic>) (<italic>CNEG</italic>)] − [(<italic>TRANS</italic>) (<italic>TNPOS</italic>) (<italic>p</italic><sub>REC</sub>) (<italic>T</italic>)]] / [(<italic>TRANS</italic>) (<italic>TNPOS</italic>) (<italic>p</italic><sub>REC</sub>) (<italic>Q</italic>)]</td>
</tr>
<tr>
<td colspan="2">Divide numerator and denominator by <italic>TPOP</italic></td>
</tr>
<tr>
<td colspan="2">$/QALY saved = [[(<italic>p</italic>) (<italic>CPOS</italic>) + (1 − <italic>p</italic>) (<italic>CNEG</italic>)] − [(<italic>TRANS</italic>) (<italic>p</italic><sub>NPOP</sub>) (<italic>p</italic><sub>REC</sub>) (<italic>T</italic>)]] / [(<italic>TRANS</italic>) (<italic>p</italic><sub>NPOP</sub>) (<italic>p</italic><sub>REC</sub>) (<italic>Q</italic>)]</td>
</tr>
<tr>
<td colspan="2">$/QALY saved = [[(<italic>p</italic>) (<italic>CPOS</italic>) + (1 − <italic>p</italic>) (<italic>CNEG</italic>)] − [(<italic>TRANS</italic>) (<italic>p</italic>) (<italic>p</italic><sub>N</sub>) (<italic>p</italic><sub>REC</sub>) (<italic>T</italic>)]] / [(<italic>TRANS</italic>) (<italic>p</italic>) (<italic>p</italic><sub>N</sub>) (<italic>p</italic><sub>REC</sub>) (<italic>Q</italic>)]</td>
</tr>
<tr>
<td colspan="2">Divide numerator and denominator by <italic>p</italic></td>
</tr>
<tr>
<td colspan="2">$/QALY saved = [[(<italic>CPOS</italic>) + [(1 − <italic>p</italic>) / <italic>p</italic>] (<italic>CNEG</italic>)] − [(<italic>TRANS</italic>) (<italic>p</italic><sub>N</sub>) (<italic>p</italic><sub>REC</sub>) (<italic>T</italic>)]] / [(<italic>TRANS</italic>) (<italic>p</italic><sub>N</sub>) (<italic>p</italic><sub>REC</sub>) (<italic>Q</italic>)]</td>
</tr>
</tbody>
</table>
</table-wrap>
</app-group>
<ack><p>PGF developed the analysis for this article on the basis of previous work by ABH and wrote the first draft. SLS and ABH then edited and substantially contributed to the writing. All of us met the criteria for authorship and agree with the article’s results and conclusions. We would like to thank Chaitra Gopalappa, PhD, for her review of the article and her contributions to the sensitivity analysis. The findings and conclusions are ours and do not necessarily represent the views of the Centers for Disease Control and Prevention. No direct funding was received for this study. We were personally salaried by our institution during the period of writing (though no specific salary was set aside or given for the writing of this article). No funding bodies had any role in study design, data collection, analysis, decision to publish, or manuscript preparation.</p></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0272989X11431609">
<label>1.</label>
<citation citation-type="journal">
<collab>Centers for Disease Control and Prevention</collab>. <article-title>Advancing HIV prevention: new strategies for a changing epidemic—United States</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2003</year>;<volume>52</volume>(<issue>15</issue>):<fpage>329</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr2-0272989X11431609">
<label>2.</label>
<citation citation-type="book">
<collab>White House Office of National AIDS Policy</collab>. <source>National HIV/AIDS Strategy for the United States</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>White House</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr3-0272989X11431609">
<label>3.</label>
<citation citation-type="journal">
<collab>Centers for Disease Control and Prevention</collab>. <article-title>Vital signs: HIV testing and diagnosis among adults—United States, 2001–2009</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2010</year>;<volume>59</volume>(<issue>47</issue>):<fpage>1550</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr4-0272989X11431609">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marks</surname><given-names>G</given-names></name>
<name><surname>Crepaz</surname><given-names>N</given-names></name>
<name><surname>Janssen</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA</article-title>. <source>AIDS</source>. <year>2006</year>;<volume>20</volume>:<fpage>1447</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr5-0272989X11431609">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kitahata</surname><given-names>MM</given-names></name>
<name><surname>Gange</surname><given-names>SJ</given-names></name>
<name><surname>Abraham</surname><given-names>AG</given-names></name><etal/>
</person-group>. <article-title>Effect of early versus deferred antiretroviral therapy for HIV on survival</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>18</issue>):<fpage>1815</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr6-0272989X11431609">
<label>6.</label>
<citation citation-type="journal">
<collab>When to Start Consortium</collab>. <article-title>Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>373</volume>(<issue>9672</issue>):<fpage>1352</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr7-0272989X11431609">
<label>7.</label>
<citation citation-type="book">
<collab>Panel on Antiretroviral Guidelines for Adults and Adolescents</collab>. <source>Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>US Department of Health and Human Services</publisher-name>; <year>2009</year>. p <fpage>1</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr8-0272989X11431609">
<label>8.</label>
<citation citation-type="journal">
<collab>Centers for Disease Control and Prevention</collab>. <article-title>Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2006</year>;<volume>55</volume>(<issue>RR14</issue>):<fpage>1</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr9-0272989X11431609">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walensky</surname><given-names>RP</given-names></name>
<name><surname>Losina</surname><given-names>E</given-names></name>
<name><surname>Malatesta</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts</article-title>. <source>Am J Public Health</source>. <year>2005</year>;<volume>95</volume>(<issue>1</issue>):<fpage>71</fpage>–<lpage>3</lpage>.</citation>
</ref>
<ref id="bibr10-0272989X11431609">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Golden</surname><given-names>MR</given-names></name>
<name><surname>Gift</surname><given-names>TL</given-names></name>
<name><surname>Brewer</surname><given-names>DD</given-names></name><etal/>
</person-group>. <article-title>Peer referral for HIV case-finding among men who have sex with men</article-title>. <source>AIDS</source>. <year>2006</year>;<volume>20</volume>(<issue>15</issue>):<fpage>1961</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr11-0272989X11431609">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Farnham</surname><given-names>PG</given-names></name>
<name><surname>Hutchinson</surname><given-names>AB</given-names></name>
<name><surname>Sansom</surname><given-names>SL</given-names></name>
<name><surname>Branson</surname><given-names>BM</given-names></name>
</person-group>. <article-title>Comparing the costs of HIV screening strategies and technologies in health-care settings</article-title>. <source>Public Health Rep</source>. <year>2008</year>;<volume>123</volume>(<supplement>Suppl 3</supplement>):<fpage>51</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr12-0272989X11431609">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silva</surname><given-names>A</given-names></name>
<name><surname>Glick</surname><given-names>NR</given-names></name>
<name><surname>Lyss</surname><given-names>SB</given-names></name><etal/>
</person-group>. <article-title>Implementing an HIV and sexually transmitted disease screening program in an emergency department</article-title>. <source>Ann Emerg Med</source>. <year>2007</year>;<volume>49</volume>(<issue>5</issue>):<fpage>564</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr13-0272989X11431609">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehta</surname><given-names>SD</given-names></name>
<name><surname>Hall</surname><given-names>J</given-names></name>
<name><surname>Greenwald</surname><given-names>JI</given-names></name>
<name><surname>Cranston</surname><given-names>K</given-names></name>
<name><surname>Skolnik</surname><given-names>PR</given-names></name>
</person-group>. <article-title>Patient risks, outcomes, and costs of voluntary HIV testing at five testing sites within a medical center</article-title>. <source>Public Health Rep</source>. <year>2008</year>;<volume>123</volume>:<fpage>608</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr14-0272989X11431609">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bogart</surname><given-names>L</given-names></name>
<name><surname>Howerton</surname><given-names>D</given-names></name>
<name><surname>Lange</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Provider-related barriers to rapid HIV testing in US urban non-profit community clinics, community-based organizations (CBOs) and hospitals</article-title>. <source>AIDS Behav</source>. <year>2010</year>;<volume>14</volume>(<issue>3</issue>):<fpage>697</fpage>–<lpage>707</lpage>.</citation>
</ref>
<ref id="bibr15-0272989X11431609">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Obermeyer</surname><given-names>CM</given-names></name>
<name><surname>Osborn</surname><given-names>M</given-names></name>
</person-group>. <article-title>The utilization of testing and counseling for HIV: a review of the social and behavioral evidence</article-title>. <source>Am J Public Health</source>. <year>2007</year>;<volume>97</volume>(<issue>10</issue>):<fpage>1762</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr16-0272989X11431609">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bogart</surname><given-names>LM</given-names></name>
<name><surname>Howerton</surname><given-names>D</given-names></name>
<name><surname>Lange</surname><given-names>J</given-names></name>
<name><surname>Becker</surname><given-names>K</given-names></name>
<name><surname>Setodji</surname><given-names>CM</given-names></name>
<name><surname>Asch</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Scope of rapid HIV testing in urban US hospitals</article-title>. <source>Public Health Rep</source>. <year>2008</year>;<volume>123</volume>:<fpage>494</fpage>–<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr17-0272989X11431609">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bogart</surname><given-names>LM</given-names></name>
<name><surname>Howerton</surname><given-names>D</given-names></name>
<name><surname>Lange</surname><given-names>J</given-names></name>
<name><surname>Becker</surname><given-names>K</given-names></name>
<name><surname>Setodji</surname><given-names>CM</given-names></name>
<name><surname>Asch</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Scope of rapid HIV testing in private nonprofit urban community health settings in the United States</article-title>. <source>Am J Public Health</source>. <year>2008</year>;<volume>98</volume>(<issue>4</issue>):<fpage>736</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr18-0272989X11431609">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hutchinson</surname><given-names>AB</given-names></name>
<name><surname>Patel</surname><given-names>P</given-names></name>
<name><surname>Sansom</surname><given-names>SL</given-names></name><etal/>
</person-group>. <article-title>Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings</article-title>. <source>PLoS Med</source>. <year>2010</year>;<volume>7</volume>(<issue>9</issue>):<fpage>e1000342</fpage>.</citation>
</ref>
<ref id="bibr19-0272989X11431609">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holtgrave</surname><given-names>DR</given-names></name>
</person-group>. <article-title>Costs and consequences of the US Centers for Disease Control and Prevention’s recommendations for opt-out HIV testing</article-title>. <source>PLoS Med</source>. <year>2007</year>;<volume>4</volume>(<issue>6</issue>):<fpage>e194</fpage>.</citation>
</ref>
<ref id="bibr20-0272989X11431609">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanders</surname><given-names>GD</given-names></name>
<name><surname>Bayoumi</surname><given-names>AM</given-names></name>
<name><surname>Sundaram</surname><given-names>V</given-names></name><etal/>
</person-group>. <article-title>Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>:<fpage>570</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr21-0272989X11431609">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paltiel</surname><given-names>AD</given-names></name>
<name><surname>Weinstein</surname><given-names>MC</given-names></name>
<name><surname>Kimmel</surname><given-names>AD</given-names></name><etal/>
</person-group>. <article-title>Expanded screening for HIV in the United States: an analysis of cost-effectiveness</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>:<fpage>586</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr22-0272989X11431609">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinkerton</surname><given-names>SD</given-names></name>
<name><surname>Holtgrave</surname><given-names>DR</given-names></name>
</person-group>. <article-title>A method for evaluating the economic efficiency of HIV behavioral risk reduction interventions</article-title>. <source>AIDS Behav</source>. <year>1998</year>;<volume>2</volume>(<issue>3</issue>):<fpage>189</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr23-0272989X11431609">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinkerton</surname><given-names>SD</given-names></name>
<name><surname>Johnson-Masotti</surname><given-names>AP</given-names></name>
<name><surname>Holtgrave</surname><given-names>DR</given-names></name>
<name><surname>Farnham</surname><given-names>PG</given-names></name>
</person-group>. <article-title>Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV</article-title>. <source>AIDS</source>. <year>2001</year>;<volume>15</volume>(<issue>7</issue>):<fpage>917</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr24-0272989X11431609">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinkerton</surname><given-names>SD</given-names></name>
<name><surname>Holtgrave</surname><given-names>DR</given-names></name>
<name><surname>DiFranceisco</surname><given-names>WJ</given-names></name>
<name><surname>Stevenson</surname><given-names>LY</given-names></name>
<name><surname>Kelly</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Cost-effectiveness of a community-level HIV risk reduction intervention</article-title>. <source>Am J Public Health</source>. <year>1998</year>;<volume>88</volume>(<issue>8</issue>):<fpage>1239</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr25-0272989X11431609">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zaric</surname><given-names>GS</given-names></name>
<name><surname>Bayoumi</surname><given-names>AM</given-names></name>
<name><surname>Brandeau</surname><given-names>ML</given-names></name>
<name><surname>Owens</surname><given-names>DK</given-names></name>
</person-group>. <article-title>The cost- effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men</article-title>. <source>Med Decis Making</source>. <year>2008</year>;<volume>28</volume>:<fpage>359</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr26-0272989X11431609">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prabhu</surname><given-names>VS</given-names></name>
<name><surname>Farnham</surname><given-names>PG</given-names></name>
<name><surname>Hutchinson</surname><given-names>AB</given-names></name><etal/>
</person-group>. <article-title>Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis</article-title>. <source>PLoS ONE</source>. <year>2011</year>;<volume>6</volume>(<issue>5</issue>):<fpage>e19936</fpage>.</citation>
</ref>
<ref id="bibr27-0272989X11431609">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ubel</surname><given-names>PA</given-names></name>
<name><surname>Hirth</surname><given-names>RA</given-names></name>
<name><surname>Chernew</surname><given-names>ME</given-names></name>
<name><surname>Fendrick</surname><given-names>AM</given-names></name>
</person-group>. <article-title>What is the price of life and why doesn’t it increase at the rate of inflation?</article-title> <source>Arch Intern Med</source>. <year>2003</year>;<volume>163</volume>(<issue>14</issue>):<fpage>1637</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr28-0272989X11431609">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braithwaite</surname><given-names>RS</given-names></name>
<name><surname>Meltzer</surname><given-names>DO</given-names></name>
<name><surname>King</surname><given-names>JT</given-names><suffix>Jr</suffix></name>
<name><surname>Leslie</surname><given-names>D</given-names></name>
<name><surname>Roberts</surname><given-names>MS</given-names></name>
</person-group>. <article-title>What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?</article-title> <source>Med Care</source>. <year>2008</year>;<volume>46</volume>(<issue>4</issue>):<fpage>349</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr29-0272989X11431609">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinstein</surname><given-names>MC</given-names></name>
</person-group>. <article-title>How much are Americans willing to pay for a quality-adjusted life year?</article-title> <source>Med Care</source>. <year>2008</year>;<volume>46</volume>(<issue>4</issue>):<fpage>343</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr30-0272989X11431609">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinkerton</surname><given-names>SD</given-names></name>
</person-group>. <article-title>How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission?</article-title> <source>AIDS</source>. <year>2007</year>;<volume>21</volume>:<fpage>1625</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr31-0272989X11431609">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prabhu</surname><given-names>VS</given-names></name>
<name><surname>Hutchinson</surname><given-names>AB</given-names></name>
<name><surname>Farnham</surname><given-names>PG</given-names></name>
<name><surname>Sansom</surname><given-names>SL</given-names></name>
</person-group>. <article-title>Sexually-acquired HIV infections in the USA due to acute-phase HIV transmission: an update</article-title>. <source>AIDS</source>. <year>2009</year>;<volume>23</volume>(<issue>13</issue>):<fpage>1792</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr32-0272989X11431609">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marks</surname><given-names>G</given-names></name>
<name><surname>Crepaz</surname><given-names>N</given-names></name>
<name><surname>Senterfitt</surname><given-names>JW</given-names></name>
<name><surname>Janssen</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2005</year>;<volume>39</volume>(<issue>4</issue>):<fpage>446</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr33-0272989X11431609">
<label>33.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Golden</surname><given-names>MR</given-names></name>
<name><surname>Stekler</surname><given-names>JD</given-names></name>
<name><surname>Wood</surname><given-names>RW</given-names></name>
</person-group>. <article-title>Trends in the frequency of HIV testing and CD4 count at time of diagnosis among persons tested through a public health program: Seattle, Washington, 1995–2008</article-title>. <conf-name>Montreal, Canada: Sixteenth Conference on Retroviruses and Opportunistic Infections</conf-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr34-0272989X11431609">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schackman</surname><given-names>BR</given-names></name>
<name><surname>Gebo</surname><given-names>KA</given-names></name>
<name><surname>Walensky</surname><given-names>RP</given-names></name><etal/>
</person-group>. <article-title>The lifetime cost of current human immunodeficiency virus care in the United States</article-title>. <source>Med Care</source>. <year>2006</year>;<volume>44</volume>(<issue>11</issue>):<fpage>990</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr35-0272989X11431609">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tengs</surname><given-names>TO</given-names></name>
<name><surname>Lin</surname><given-names>TH</given-names></name>
</person-group>. <article-title>A meta-analysis of utility estimates for HIV/AIDS</article-title>. <source>Med Decis Making</source>. <year>2002</year>;<volume>22</volume>(<issue>6</issue>):<fpage>475</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr36-0272989X11431609">
<label>36.</label>
<citation citation-type="journal">
<collab>Centers for Disease Control and Prevention</collab>. <article-title>Prevalence and awareness of HIV infection among men who have sex with men: 21 cities, United States, 2008</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2010</year>;<volume>59</volume>(<issue>37</issue>):<fpage>1201</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr37-0272989X11431609">
<label>37.</label>
<citation citation-type="journal">
<collab>Centers for Disease Control and Prevention</collab>. <article-title>Results of the expanded HIV testing initiative: 25 jurisdictions, United States, 2007–2010</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2011</year>;<volume>60</volume>(<issue>24</issue>):<fpage>805</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr38-0272989X11431609">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanna</surname><given-names>DB</given-names></name>
<name><surname>Tsoi</surname><given-names>BW</given-names></name>
<name><surname>Begier</surname><given-names>EM</given-names></name>
</person-group>. <article-title>Most positive HIV Western blot tests do not diagnose new cases in New York City: implications for HIV testing programs</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2009</year>;<volume>51</volume>(<issue>5</issue>):<fpage>609</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr39-0272989X11431609">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holtgrave</surname><given-names>DR</given-names></name>
<name><surname>Pinkerton</surname><given-names>SD</given-names></name>
</person-group>. <article-title>Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>1997</year>;<volume>16</volume>(<issue>1</issue>):<fpage>54</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr40-0272989X11431609">
<label>40.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Gold</surname><given-names>MR</given-names></name>
<name><surname>Siegel</surname><given-names>JE</given-names></name>
<name><surname>Russell</surname><given-names>LB</given-names></name>
<name><surname>Weinstein</surname><given-names>MC</given-names></name>
</person-group>, eds. <source>Cost-Effectiveness in Health and Medicine</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>1996</year>.</citation>
</ref>
<ref id="bibr41-0272989X11431609">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hutchinson</surname><given-names>AB</given-names></name>
<name><surname>Branson</surname><given-names>BM</given-names></name>
<name><surname>Kim</surname><given-names>A</given-names></name>
<name><surname>Farnham</surname><given-names>PG</given-names></name>
</person-group>. <article-title>A meta- analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status</article-title>. <source>AIDS</source>. <year>2006</year>;<volume>20</volume>(<issue>12</issue>):<fpage>1597</fpage>–<lpage>604</lpage>.</citation>
</ref>
<ref id="bibr42-0272989X11431609">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patel</surname><given-names>P</given-names></name>
<name><surname>Klausner</surname><given-names>JD</given-names></name>
<name><surname>Bacon</surname><given-names>OM</given-names></name><etal/>
</person-group>. <article-title>Detection of acute HIV infections in high-risk patients in California</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2006</year>;<volume>42</volume>(<issue>1</issue>):<fpage>75</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr43-0272989X11431609">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campos-Outcalt</surname><given-names>D</given-names></name>
<name><surname>Mickey</surname><given-names>T</given-names></name>
<name><surname>Weisbuch</surname><given-names>J</given-names></name>
<name><surname>Jones</surname><given-names>R</given-names></name>
</person-group>. <article-title>Integrating routine HIV testing into a public health STD clinic</article-title>. <source>Public Health Rep</source>. <year>2006</year>;<volume>121</volume>(<issue>2</issue>):<fpage>175</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr44-0272989X11431609">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinkerton</surname><given-names>SD</given-names></name>
<name><surname>Bogart</surname><given-names>LM</given-names></name>
<name><surname>Howerton</surname><given-names>D</given-names></name>
<name><surname>Snyder</surname><given-names>S</given-names></name>
<name><surname>Becker</surname><given-names>K</given-names></name>
<name><surname>Asch</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Cost of rapid HIV testing at 45 US hospitals</article-title>. <source>AIDS Patient Care STDs</source>. <year>2010</year>;<volume>24</volume>(<issue>7</issue>):<fpage>409</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr45-0272989X11431609">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Helms</surname><given-names>DJ</given-names></name>
<name><surname>Weinstock</surname><given-names>HS</given-names></name>
<name><surname>Mahle</surname><given-names>KC</given-names></name><etal/>
</person-group>. <article-title>HIV testing frequency among men who have sex with men attending sexually transmitted disease clinics: implications for HIV prevention and surveillance</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2009</year>;<volume>50</volume>(<issue>3</issue>):<fpage>320</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr46-0272989X11431609">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Long</surname><given-names>EF</given-names></name>
<name><surname>Brandeau</surname><given-names>ML</given-names></name>
<name><surname>Owens</surname><given-names>DK</given-names></name>
</person-group>. <article-title>The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States</article-title>. <source>Ann Intern Med</source>. <year>2010</year>;<volume>153</volume>(<issue>12</issue>):<fpage>778</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr47-0272989X11431609">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hsieh</surname><given-names>Y-H</given-names></name>
<name><surname>Jung</surname><given-names>JJ</given-names></name>
<name><surname>Shahan</surname><given-names>JB</given-names></name><etal/>
</person-group>. <article-title>Outcomes and cost analysis of 3 operational models for rapid HIV testing services in an academic inner-city emergency department</article-title>. <source>Ann Emerg Med</source>. <year>2011</year>;<volume>58</volume>(<issue>1</issue>)(<supplement>Suppl 1</supplement>):<fpage>S133</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr48-0272989X11431609">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hall</surname><given-names>HI</given-names></name>
<name><surname>Song</surname><given-names>R</given-names></name>
<name><surname>Rhodes</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Estimation of HIV Incidence in the United States</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>300</volume>(<issue>5</issue>):<fpage>520</fpage>–<lpage>9</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>